Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis
Tóm tắt
The clinical and economic consequences of the emergence of multidrug-resistant Gram-negative bacteria in the intensive care unit (ICU) setting, combined with the high mortality rate among patients with nosocomial pneumonia, have stimulated a search for alternative therapeutic options to treat such infections. The use of adjunctive therapy with aerosolized colistin represents one of these. There is extensive experience with use of aerosolized colistin by patients with cystic fibrosis, but there is a lack of data regarding the use of aerosolized colistin in patients without cystic fibrosis. We conducted the present study to assess the safety and effectiveness of aerosolized colistin as an adjunct to intravenous antimicrobial therapy for treatment of Gram-negative nosocomial pneumonia. We retrospectively reviewed the medical records of patients hospitalized in a 450-bed tertiary care hospital during the period from October 2000 to January 2004, and who received aerosolized colistin as adjunctive therapy for multidrug-resistant pneumonia. Eight patients received aerosolized colistin. All patients had been admitted to the ICU, with mean Acute Physiological and Chronic Health Evaluation II scores on the day of ICU admission and on day 1 of aerosolized colistin administration of 14.6 and 17.1, respectively. Six of the eight patients had ventilator-associated pneumonia. The responsible pathogens were Acinetobacter baumannii (in seven out of eight cases) and Pseudomonas aeruginosa (in one out of eight cases) strains. Half of the isolated pathogens were sensitive only to colistin. The daily dose of aerosolized colistin ranged from 1.5 to 6 million IU (divided into three or four doses), and the mean duration of administration was 10.5 days. Seven out of eight patients received concomitant intravenous treatment with colistin or other antimicrobial agents. The pneumonia was observed to respond to treatment in seven out of eight patients (four were cured and three improved [they were transferred to another facility]). One patient deteriorated and died from septic shock and multiple organ failure. Aerosolized colistin was well tolerated by all patients; no bronchoconstriction or chest tightness was reported. Aerosolized colistin may be a beneficial adjunctive treatment in the management of nosocomial pneumonia (ventilator associated or not) due to multidrug-resistant Gram-negative bacteria.
Tài liệu tham khảo
Montero A, Corbella X, Ariza J: Clinical relevance of Acinetobacter baumannii ventilator-associated pneumonia. Crit Care Med 2003, 31: 2557-2559. 10.1097/01.CCM.0000089937.38406.9F
Chastre J, Fagon JY: Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002, 165: 867-903.
Salas CJ, Cabezas FT, de Soria Alvarez-Ossorio, Rogado Gonzalez MC, Delgado FM, Diez GF: Nosocomial infection/colonization of the respiratory tract caused by Acinetobacter baumannii in an internal medicine ward [in Spanish]. An Med Interna 2002, 19: 511-514.
Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, Barrero-Almodovar AE, Garcia-Garmendia JL, Bernabeu-WittelI M, Gallego-Lara SL, Madrazo-Osuna J: Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 2003, 36: 1111-1118. 10.1086/374337
Bauldoff GS, Nunley DR, Manzetti JD, Dauber JH, Keenan RJ: Use of aerosolized colistin sodium in cystic fibrosis patients awaiting lung transplantation. Transplantation 1997, 64: 748-752. 10.1097/00007890-199709150-00015
Beringer P: The clinical use of colistin in patients with cystic fibrosis. Curr Opin Pulm Med 2001, 7: 434-440. 10.1097/00063198-200111000-00013
Zylberberg H, Vargaftig J, Barbieux C, Pertuiset N, Rothschild C, Viard JP: Prolonged efficiency of secondary prophylaxis with colistin aerosols for respiratory infection due to Pseudomonas aeruginosa in patients infected with human immunodeficiency virus. Clin Infect Dis 1996, 23: 641-643.
Hamer DH: Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin. Am J Respir Crit Care Med 2000, 162: 328-330.
Green ST, Nathwani D, Gourlay Y, McMenamin J, Goldberg DJ, Kennedy DH: Nebulized colistin (polymyxin E) for AIDS-associated Pseudomonas aeruginosa pneumonia. Int J STD AIDS 1992, 3: 130-131.
Rose HD, Pendharker MB, Snider GL, Kory RC: Evaluation of sodium colistimethate aerosol in gram-negative infections of the respiratory tract. J Clin Pharmacol J New Drugs 1970, 10: 274-281.
Feeley TW, Du Moulin GC, Hedley-Whyte J, Bushnell LS, Gilbert JP, Feingold DS: Aerosol polymyxin and pneumonia in seriously ill patients. N Engl J Med 1975, 293: 471-475.
Klastersky J, Hensgens C, Noterman J, Mouawad E, Meunier-Carpentier F: Endotracheal antibiotics for the prevention of tracheobronchial infections in tracheotomized unconscious patients. A comparative study of gentamicin and aminosidin-polymyxin B combination. Chest 1975, 68: 302-306.
Wayne P: Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically. Approved standards document M7-A5. In National Committee for Clinical Laboratory Standards 2000.
Wayne P: Performance standard for antimicrobial susceptibility testing. Document M100-S10. In National Committee for Clinical Laboratory Standards 2000.
Gaynes RP, Horan TC: Surveillance of nosocomial infections. Appendix A: CDC definitions of nosocomial infections. In Hospital Epidemiology and Infection control. Edited by: Mayhall CG. Baltimore: Williams & Wilkins; 1996:1-14.
Michalopoulos AS, Tsiodras S, Rellos K, Melentzopoulos S, Falagas ME: Colistin treatment in patients with ICU-acquired infections due to multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect 2004, in press.
Levin AS, Barone AA, Penco J, Santos MV, Marinho IS, Arruda EA, Manrique EI, Costa SF: Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii . Clin Infect Dis 1999, 28: 1008-1011.
Linden PK, Kusne S, Coley K, Fontes P, Kramer DJ, Paterson D: Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa . Clin Infect Dis 2003, 37: e154-e160. 10.1086/379611
Pino G, Conterno G, Colongo PG: Clinical observations on the activity of aerosol colimycin and of endobronchial instillations of colimycin in patients with pulmonary suppurations [in Italian]. Minerva Med 1963, 54: 2117-2122.
Marschke G, Sarauw A: Polymyxin inhalation therapeutic hazard. Ann Intern Med 1971, 74: 144-145.
Green ST, Nathwani D, Gourlay Y, McMenamin J, Goldberg DJ, Kennedy DH: Nebulized colistin (polymyxin E) for AIDS-associated Pseudomonas aeruginosa pneumonia. Int J STD AIDS 1992, 3: 130-131.
Hamer DH: Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin. Am J Respir Crit Care Med 2000, 162: 328-330.
Zylberberg H, Vargaftig J, Barbieux C, Pertuiset N, Rothschild C, Viard JP: Prolonged efficiency of secondary prophylaxis with colistin aerosols for respiratory infection due to Pseudomonas aeruginosa in patients infected with human immunodeficiency virus. Clin Infect Dis 1996, 23: 641-643.
Beringer P: The clinical use of colistin in patients with cystic fibrosis. Curr Opin Pulm Med 2001, 7: 434-440. 10.1097/00063198-200111000-00013
Jensen T, Pedersen SS, Garne S, Heilmann C, Hoiby N, Koch C: Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother 1987, 19: 831-838.
Valerius NH, Koch C, Hoiby N: Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 1991, 338: 725-726. 10.1016/0140-6736(91)91446-2
Littlewood JM, Miller MG, Ghoneim AT, Ramsden CH: Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis [letter]. Lancet 1985, 1: 865. 10.1016/S0140-6736(85)92222-6
Faurisson F, Dessanges JF, Grimfeld A, Beaulieu R, Kitzis MD, Peytavin G, Lefebvre JP, Farinotti R, Sautegeau A: Nebulizer performance: AFLM study. Association Francaise de Lutte contre la Mucoviscidose. Respiration 1995,62(Suppl 1):13-18.
Hung JC, Hambleton G, Super M: Evaluation of two commercial jet nebulisers and three compressors for the nebulisation of antibiotics. Arch Dis Child 1994, 71: 335-338.
Le Brun PP, de Boer AH, Mannes GP, de Fraiture DM, Brimicombe RW, Touw DJ, Vinks AA, Frijlink HW, Heijerman HG: Dry powder inhalation of antibiotics in cystic fibrosis therapy: part 2. Inhalation of a novel colistin dry powder formulation: a feasibility study in healthy volunteers and patients. Eur J Pharm Biopharm 2002, 54: 25-32. 10.1016/S0939-6411(02)00044-9
Weber A, Morlin G, Cohen M, Williams-Warren J, Ramsey B, Smith A: Effect of nebulizer type and antibiotic concentration on device performance. Pediatr Pulmonol 1997, 23: 249-260.
Cunningham S, Prasad A, Collyer L, Carr S, Lynn IB, Wallis C: Bronchoconstriction following nebulised colistin in cystic fibrosis. Arch Dis Child 2001, 84: 432-433. 10.1136/adc.84.5.432
Maddison J, Dodd M, Webb AK: Nebulized colistin causes chest tightness in adults with cystic fibrosis. Respir Med 1994, 88: 145-147. 10.1016/0954-6111(94)90028-0
Schultsz C, Meester HH, Kranenburg AM, Savelkoul PH, Boeijen-Donkers LE, Kaiser AM, de Bree R, Snow GB, Vandenbroucke-Grauls CJ: Ultra-sonic nebulizers as a potential source of methicillin-resistant Staphylococcus aureus causing an outbreak in a university tertiary care hospital. J Hosp Infect 2003, 55: 269-275. 10.1016/S0195-6701(03)00263-9
Koss JA, Conine TA, Eitzen HE, LoSasso AM: Bacterial contamination potential of sterile, prefilled humidifiers and nebulizer reservoirs. Heart Lung 1979, 8: 1117-1121.